Reference
Government of Canada. TECENTRIQ (atezolizumab) - Risk of Myocarditis. Internet Document : 14 Feb 2018. Available from: URL: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65990a-eng.php
Rights and permissions
About this article
Cite this article
Risk of severe cases of myocarditis with atezolizumab. Reactions Weekly 1691, 2 (2018). https://doi.org/10.1007/s40278-018-42257-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-42257-1